Biology of the Striatum

  • André Barbeau


In the last 20 years, there has been a significant advance in our understanding of the pathophysiology and biochemistry of disorders of the basal ganglia. The first steps were taken with the demonstration of the role of copper and ceruloplasmin in hepatolenticular degeneration, or Wilson’s disease. A few years later, it was found that dopamine is highly concentrated in the basal ganglia of the brain and that it is deficient in Parkinson’s disease. This led to the use of the precursor L-dopa in the therapy of Parkinson’s disease, a development which proved to be important both for the patients and for the attention paid by neurobiologists to this part of the brain.


Basal Ganglion Tyrosine Hydroxylase Brain Stem Dopamine Receptor Homovanillic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Barbeau and F. H. McDowell, “L-DOPA and Parkinsonism,” pp. 1–433, F. A. Davis, Philadelphia (1970).Google Scholar
  2. 2.
    A. Barbeau, l-DOPA therapy in Parkinson’s disease: A critical review of nine years’ experience, Can. Med. Ass. J 101:781–800(1969).Google Scholar
  3. 3.
    N. E. Andén, A. Dahlström, K. Fuxe, and K. Larsson, Mapping out of catecholamine and 5-hydroxytryptamine neurons innervating the telencephalon and the diencephalon, Life Sci 4:1275–1280 (1965).CrossRefGoogle Scholar
  4. 4.
    A. Barbeau, Functions of the striatum, in “Monoamines, noyaux gris centraux et syndrome de Parkinson,” (J. de Ajuriaguerra and G. Gauthier, eds.) pp. 385–402, Masson et Cie, Paris (1971).Google Scholar
  5. 5.
    A. Barbeau, Role of dopamine in the nervous system, in “Monographs in Human Genetics” (J. François, ed.) Vol. 6, pp. 114–136, Karger, Basel (1972).Google Scholar
  6. 6.
    A. Barbeau, Contributions of levodopa therapy to the neuropharmacology of akinesia, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 1, pp. 152–174 Hans Huber, Publ., Berne (1972).Google Scholar
  7. 7.
    A. Barbeau, Dopamine and mental function, inl-DOPA and Behavior” (S. Malitz, ed.) pp. 9–33, Raven Press, New York (1972).Google Scholar
  8. 8.
    N. A. Buchwald, C. D. Hull, L. M. Vernon, and G. A. Bernardi, Physiological and psychological aspects of basal ganglia functions, in “Psychotropic Drugs and Dysfunctions of the Basal Ganglia,” pp. 82–92, P.H.S. Publication No. 1938, Government Printing Office, Washington, D.C. (1969).Google Scholar
  9. 9.
    D. Albe-Fessard, G. Guiot, Y. Lamarre, and G. Arfel, Activation of thalamocortical projections related to tremorogenic processes, in “The Thalamus” (D. Purpura and M. D. Yahr, eds.) pp. 237–253, Columbia University Press, New York (1966).Google Scholar
  10. 10.
    W. R. Hess, “Vegetative Funktionen und Zwischenhirn,” Schwabe, Basel (1946).Google Scholar
  11. 11.
    D. Denny-Brown, Diseases of the basal ganglia. Their relation to disorders of movements, Lancet 2:1099 (1960).CrossRefGoogle Scholar
  12. 12.
    R. Jung and R. Hassler, The extrapyramidal motor system, in “Handbook of Physiology,” Vol. 2, pp. 863–927, American Physiological Society, Washington, D.C. (1960).Google Scholar
  13. 13.
    A. Carlsson, The occurrence, distribution and physiological role of catecholamines in the nervous system, Pharmacol. Rev 11:490–493 (1959).Google Scholar
  14. 14.
    O. Hornykiewicz, Dopamine (3-hydroxytyramine) and brain function, Pharmacol. Rev 18:925–964 (1966).Google Scholar
  15. 15.
    M. Joubert and A. Barbeau, Akinesia in Parkinson’s disease, in “Progress in Neuro-Genetics” (A. Barbeau and J. R. Brunette, eds.) pp. 366–376, Excerpta Medica Foundation, Amsterdam (1969).Google Scholar
  16. 16.
    J. de Ajuriaguerra, La notion d’akinésie, in “Monoamines, noyaux gris centraux et syndrome de Parkinson” (J. de Ajuriaguerra and G. Gauthier, eds.) pp. 565–579 Masson et Cie, Paris (1971).Google Scholar
  17. 17.
    J. Brumlik and B. Boshes, The mechanism of bradykinesia in Parkinsonism, Neurology 16:337–344 (1966).CrossRefGoogle Scholar
  18. 18.
    K. Kleist, “Gehirnpathologie,” J. A. Barth, Leipzig (1934).Google Scholar
  19. 19.
    R. S. Schwab and I. Zieper, Effects of mood, motivation, stress and alertness on the performance of Parkinson’s disease, Psychiat. Neurol (Basel) 150:345–357 (1965).CrossRefGoogle Scholar
  20. 20.
    A. Barbeau, G. F. Murphy, and T. L. Sourkes, Excretion of dopamine in diseases of basal ganglia, Science 133:1706–1707 (1961).CrossRefGoogle Scholar
  21. 21.
    A. Barbeau, Dopamine and dopamine metabolites in Parkinson’s disease. A review, Proc. Aust. Ass. Neurologists 5:95–100 (1968).Google Scholar
  22. 22.
    A. Barbeau, La maladie de Parkinson et 1e métabolisme des amines cérébrales, Rev. Praticien 20:5165–5173 (1970).Google Scholar
  23. 23.
    R. Papeschi, P. Molina-Negro, T. L. Sourkes, J. Hardy, and C. Bertrand, Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson’s disease and other dyskinesias, Neurology 20:991–1001 (1970).CrossRefGoogle Scholar
  24. 24.
    U. K. Rinne and V. Sonninen, Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson’s disease, Neurology 22:62–69 (1972).CrossRefGoogle Scholar
  25. 25.
    W. Birkmayer and O. Hornykiewicz, Der l-dioxyphenylalanin (L-DOPA)-Effekt beim Parkinson Syndrom des Menschen: Zur Pathogenese und Behandlung des Parkinson Akinese, Arch. Psychiat. Nervenkrank 203:560–572 (1962).CrossRefGoogle Scholar
  26. 26.
    H. Corrodi, K. Fuxe, and U. Ungerstedt, Evidence for a new type of dopamine receptor stimulating agent, J. Pharm. Pharmacol 23:989–991 (1971).CrossRefGoogle Scholar
  27. 27.
    A. M. Ernst, Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats, Psychopharmacologia 10:316–323 (1967).CrossRefGoogle Scholar
  28. 28.
    R. S. Schwab, L. V. Amador, and J. Y. Lettvin, Apomorphine in Parkinson disease, Trans. Am. Neurol. Ass 76:251–253 (1951).Google Scholar
  29. 29.
    J. Braham, I. Sarova-Pinhas, and Y. Goldhammer, Apromorphine in Parkinsonian tremor. Brit Med. J 3:768 (1970).CrossRefGoogle Scholar
  30. 30.
    P. Castaigne, D. LaPlanne, and G. Dordain, Clinical experimentation with apomorphine in Parkinson’s disease, Res. Commun. Chem. Pathol. Pharmacol 2:154–158 (1971).Google Scholar
  31. 31.
    G. C. Cotzias, P. S. Papavasiliou, C. Fehling, B. Kaufman, and I. Mena, Similarities bebetween neurologic effects of l-DOPA and apomorphine, New Engl. J. Med 232:31–33 (1970).CrossRefGoogle Scholar
  32. 32.
    S. E. Düby, L. K. Dahl, and G. C. Cotzias, Coupling of hypotensive and anti-Parkinson effects with two dopaminergic drugs, Trans. Ass. Am. Physicians 84:289–296 (1971).Google Scholar
  33. 33.
    U. Ungerstedt, L. L. Butcher, S. G. Butcher, N. E. Anden, and K. Fuxe, Direct chemical Stimulation of dopaminergic mechanisms in the neostriatum of the rat, Brain Res 14:461–470 (1969).CrossRefGoogle Scholar
  34. 34.
    K. M. Taylor and S. H. Snyder, Amphetamine: Differentiation by D and L isomers of behavior involving brain norepinephrine or dopamine, Science 168:1487–1488 (1970).CrossRefGoogle Scholar
  35. 35.
    S. H. Snyder, K. M. Taylor, J. T. Coyle, and J. L. Meyerhoff, The role of brain dopamine in behavioral regulation and the actions of psychotropic drugs, Am. J. Psychol 127:199–207 (1970).Google Scholar
  36. 36.
    A. Barbeau, H. Mars, and L. Gillo-Joffroy, Adverse clinical side-effects of levodopa therapy, in “Recent Advances in Parkinson’s Disease” (F. H. McDowell and C. H. Markham, eds.) Vol. 8, pp. 203–207, Contemporary Neurology, F. A. Davis, Philadelphia (1971).Google Scholar
  37. 37.
    A. Olivier, A. Parent, H. Simard, and L. J. Poirier, Cholinesterasic striatopallidal and striatonigral efferents in the cat and the monkey, Brain Res 18:273–282 (1970).CrossRefGoogle Scholar
  38. 38.
    N. E. Andén, M. G. M. Jukes, and A. Lundberg, The effect of DOPA on the spinal cord. 2. A pharmacological analysis, Acta Phys. Scand 67:387–397 (1966).CrossRefGoogle Scholar
  39. 39.
    N. E. Andén, A. Rubenson, K. Fuxe, and T. Hökfelt, Evidence for dopamine receptor Stimulation by apomorphine, J. Pharm. Pharmacol 19:637–639 (1967).CrossRefGoogle Scholar
  40. 40.
    A. Barbeau, Dopamine and disease, Can. Med. Ass. J 103:824–832 (1970).Google Scholar
  41. 41.
    G. Bryson, Biogenic amines in normal and abnormal behavioral states, Clin. Chem 17:5–26 (1971).Google Scholar
  42. 42.
    B. B. Brodie and W. D. Reid, Serotonin in brain: Functional considerations, Advan. Pharmacol 6:97 (1968).CrossRefGoogle Scholar
  43. 43.
    J. J. Schildkraut, The catecholamine hypothesis of affective disorders: A review of supporting evidence, Am. J. Psychol 122:509–522. (1965).Google Scholar
  44. 44.
    F. A. Mettler and A. Crandell, Relation between parkinsonism and psychiatric disorder, J. Nerv. Ment. Dis 129:551–563 (1959).CrossRefGoogle Scholar
  45. 45.
    N. S. Kline, and F. A. Mettler, The extrapyramidal system and schizophrenia, in “Extrapyramidal System and Neuroleptics” (J. M. Bordeleau, ed.) pp 487–491, Presses de l’Université de Montréal, Montréal (1961).Google Scholar
  46. 46.
    E. L. Bliss, and J. Ailion, Relationship of stress and activity to brain dopamine and homovanillic acid, Life Sci 10:1161–1169 (1971).CrossRefGoogle Scholar
  47. 47.
    M. I. Botez and A. Barbeau, Role of subcortical structures and particularly of the thalamus in the mechanisms of speech and language. A review, Intern. J. Neurol 8:300–320 (1971).Google Scholar
  48. 48.
    J. V. Beardsley and F. Puletti, Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment, Arch. Neurol 25:145–150 (1971).CrossRefGoogle Scholar
  49. 49.
    R. Klaiber, J. Siegfried, W. H. Ziegler, and E. Perret, Psychomotor effects of l-DOPA combined with a decarboxylase inhibitor on parkinsonian patients, Europ. J. Clin. Pharmacol 3:172–175 (1971).CrossRefGoogle Scholar
  50. 50.
    J. Barbizet, Rôle du lobe frontal dans les conduites mnésiques, Presse Méd 79:2033–2037 (1971).Google Scholar
  51. 51.
    G.C. Marsh, C. H. Markham, and R. Ansel, Levodopa’s awakening effect on patients with parkinsonism, J. Neurol. Neurosurg. Psychiat 34:209–218 (1971).CrossRefGoogle Scholar
  52. 52.
    T. C. Gutherie, H. S. Dunbar, and A. Weider, l-DOPA: Effect on highest integrative functions in parkinsonism, Trans. Am. Neurol. Ass 95:250–252 (1970).Google Scholar
  53. 53.
    A. W. Loranger, H. Goodell J. E. Lee, and F. H. McDowell, Levodopa treatment of Parkinson’s syndrome. Improved intellectual functioning, Arch. Gen. Psychiat 26:163–168 (1972).CrossRefGoogle Scholar
  54. 54.
    M. Riklan, Levodopa and behavior, Neurology 22:(Part 2):43–55 (1972).CrossRefGoogle Scholar
  55. 55.
    D. C. Garron, H. L. Klawans, and F. Narin, Intellectual functioning of persons with idiopathic parkinsonism, J. Nerv. Ment. Dis 154:445–452 (1972).CrossRefGoogle Scholar
  56. 56.
    A. Barbeau, Long term appraisal of levodopa therapy, Neurology 22:(Part 2):22–24 (1972).CrossRefGoogle Scholar
  57. 57.
    M. I. Botez and A. Barbeau, The neuropsychology of akinesia. 1. Kohs block design test before and after levodopa therapy, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 2, Hans Huber Publ., Berne (1972).Google Scholar
  58. 58.
    E. A. Spiegel and E. G. Szekely, Prolonged sitmulation of the head of the caudate nucleus, Arch. Neurol 4:55–61 (1961).CrossRefGoogle Scholar
  59. 59.
    U. Ungerstedt, 6-Hydroxydopamine-induced degeneration of central monoamine neurons, Europ. J. Pharmacol 5:107–110 (1968).CrossRefGoogle Scholar
  60. 60.
    H. Thoenen, R. A. Mueller, and J. Axelrod, Trans-synaptic induction of tyrosine hydroxylase, J. Pharmacol. Exptl. Therap 169:249–254 (1969).Google Scholar
  61. 61.
    B. Jacks, J. De Champlain, and J. P. Cordeau, Effect of 6-OH-dopamine on the central nervous system of rats, Proc. Can. Fed. Biol. Soc 13:136 (1970).Google Scholar
  62. 62.
    A. Pletscher, Regulation of catecholamine turnover by variations of enzyme levels, Pharmacol Rev 24:225–232 (1972).Google Scholar
  63. 63.
    P. B. Molinoff and J. Axelrod, Biochemistry of catecholamines, Ann. Rev. Biochem 40:465–500 (1971).CrossRefGoogle Scholar
  64. 64.
    K. Yamada, J. L. Minnich, J. Donaldson, and A. Barbeau, Effect of 3,4-dihydroxyphenyl-acetic acid on catecholamines and serotonin in rat striatum, J. Neurol. Sci 18:311–315 (1973).CrossRefGoogle Scholar
  65. 65.
    R. A. Mueller, H. Thoenen, and J. Axelrod, Effect of pituitary and ACTH on the maintenance of basal tyrosine hydroxylase activity in the rat adrenal gland, Endocrinology 86:751–755 (1970).CrossRefGoogle Scholar
  66. 66.
    R. Weinshilbaum and J. Axelrod, Dopamine-β-hydroxylase activity in the rat after hypophysectomy, Endocrinology 87:894–899 (1970).CrossRefGoogle Scholar
  67. 67.
    H. Friesen, H. Guyda, P. Hwang, J. E. Tyson, and A. Barbeau, Functional evaluation of prolactin secretion. A guide to therapy, J. Clin. Invest 51:706–709 (1972).CrossRefGoogle Scholar
  68. 68.
    S. W. Spaulding, G. N. Burrow, R. Donabedian, and M. Van Woert, l-DOPA suppression of thyrotropin releasing hormone response in man, J. Clin. Endocrinol. Metab 35:182–185 (1972).CrossRefGoogle Scholar
  69. 69.
    D. Ganten, J. L. Minnich, P. Granger, K. Hayduk, H. M. Brecht, A. Barbeau, R. Boucher, and J. Genest, Angiotensin-forming enzyme in brain tissue, Science 173:64–65 (1971).CrossRefGoogle Scholar
  70. 70.
    J. L. Minnich, D. Ganten, A. Barbeau, and J. Genest, Subcellular localization of cerebral renin-like activity, in “Hypertension ‘72” (J. Genest and E. Koiw, eds.) pp. 432–435, Springer-Verlag, Berlin (1972).Google Scholar
  71. 71.
    J. L. Minnich, J. Donaldson, and A. Barbeau, Modification des concentrations cérébrales en monoamines par l’angiotensine, Union Med. Can 102:903–906 (1973).Google Scholar
  72. 72.
    E. Roberts, An hypothesis suggesting that there is a defect in the GABA system in schizophrenia, Neurosc. Res. Progr. Bull 10:468–482 (1972).Google Scholar
  73. 73.
    A. Barbeau, Biochemistry of Parkinson’s disease, Excerpta Med. Intern. Congr. Ser 38:152 (1961).Google Scholar
  74. 74.
    A. Barbeau, Treatment of Parkinson’s disease with levodopa and Ro 4-4602. Review and present status, in “Advances in Neurology,” vol. 2 (M. D. Yahr, ed.), Raven Press, New York, pp. 173–198 (1973).Google Scholar
  75. 75.
    A. Barbeau, Biochemistry of Huntington’s chorea, in “Huntingtons Chorea: 1872–1972” (A. Barbeau, T. N. Chase, and G. W. Paulson, eds.), Raven Press, New York (1973).Google Scholar
  76. 76.
    A. Barbeau, The biochemistry of Huntington’s chorea. Recent developments, Psychiat. Forum (1973).Google Scholar
  77. 77.
    A. J. Kastin and A. Barbeau, Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson’s disease, Can Med. Ass. J 107:1079–1081 (1972).Google Scholar
  78. 78.
    O. Hornykiewicz, Biochemical and pharmacological aspects of akinesia, in “Parkinson’s Disease (Rigidity, Akinesia, Behavior)” (J. Siegfried, ed.) Vol. 1, pp. 127–149, Hans Huber Publ., Berne (1972).Google Scholar
  79. 79.
    O. Hornykiewicz, Dopamine: Its physiology, pharmacology and pathological neurochemistry, in “Biogenic Amines and Physiological Membranes” (J. H. Biel and L. G. Abood, eds.) Part 2, pp. 173–258, Dokker, New York (1971).Google Scholar
  80. 80.
    O. Hornykiewicz, Neurochemistry of parkinsonism, in “Handbook of Neurochemistry” (A. Lajtha, ed.) Vol. 7, pp. 465–501, Plenum Press, New York. (1972).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1973

Authors and Affiliations

  • André Barbeau
    • 1
  1. 1.Department of NeurobiologyClinical Research Institute of MontrealMontrealCanada

Personalised recommendations